^
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
02/06/2025
Initiation :
12/12/2014
Primary completion :
03/31/2021
Completion :
09/19/2025
EGFR
|
doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)
Phase 2
Imvax
Active, not recruiting
Last update posted :
05/31/2024
Initiation :
03/20/2023
Primary completion :
01/01/2025
Completion :
07/01/2027
MGMT
|
temozolomide • IGV-001
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
02/14/2023
Initiation :
12/05/2019
Primary completion :
12/15/2022
Completion :
12/15/2022
CDK4 • EWSR1 • IGF1 • FLI1 • FUS
|
Ibrance (palbociclib) • ganitumab (AMG 479)
Phase 1
SCRI Development Innovations, LLC
Completed
Last update posted :
05/03/2022
Initiation :
07/01/2010
Primary completion :
05/01/2013
Completion :
05/01/2013
KRAS • ALK
|
KRAS mutation • KRAS wild-type • RAS wild-type
|
everolimus • linsitinib (ASP7487)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
02/08/2022
Initiation :
03/01/2008
Primary completion :
09/01/2012
Completion :
02/25/2014
EGFR
|
erlotinib • gemcitabine • cixutumumab (IMC A12)
Phase 1b/2
MedImmune LLC
Completed
Last update posted :
06/02/2020
Initiation :
06/13/2011
Primary completion :
06/28/2019
Completion :
06/28/2019
HER-2 • IGF2
|
exemestane • dusigitumab (MEDI-573)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
03/24/2020
Initiation :
07/30/2008
Primary completion :
01/07/2014
Completion :
10/15/2019
HER-2
|
HER-2 positive • HER-2 amplification
|
Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
03/19/2020
Initiation :
10/17/2011
Primary completion :
08/15/2018
Completion :
08/15/2018
EGFR
|
Erbitux (cetuximab) • cixutumumab (IMC A12)
Phase 1/2
Astellas Pharma Inc
Completed
Last update posted :
11/19/2019
Initiation :
08/05/2009
Primary completion :
08/01/2014
Completion :
08/25/2014
MUC16
|
MUC16 elevation
|
paclitaxel • linsitinib (ASP7487)
Phase 2
Eli Lilly and Company
Completed
Last update posted :
09/20/2019
Initiation :
04/01/2011
Primary completion :
01/01/2013
Completion :
06/01/2016
IGF1 • IGFBP3
|
cisplatin • pemetrexed • cixutumumab (IMC A12)
Phase 2
Eli Lilly and Company
Completed
Last update posted :
09/20/2019
Initiation :
02/01/2009
Primary completion :
07/01/2011
Completion :
05/01/2016
IGF1 • IGF2
|
cixutumumab (IMC A12) • octreotide acetate solution for injection
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
05/15/2019
Initiation :
05/17/2011
Primary completion :
08/15/2017
Completion :
08/15/2017
EGFR • ALK
|
EGFR mutation • ALK fusion
|
Avastin (bevacizumab) • carboplatin • pemetrexed • cixutumumab (IMC A12)
Phase 1
MedImmune LLC
Completed
Last update posted :
03/04/2019
Initiation :
03/09/2009
Primary completion :
09/11/2012
Completion :
09/11/2012
IGF1 • IGF2
|
dusigitumab (MEDI-573)
Phase 2
Astellas Pharma Inc
Completed
Last update posted :
01/24/2019
Initiation :
04/08/2011
Primary completion :
03/01/2013
Completion :
09/01/2014
EGFR
|
EGFR mutation • EGFR exon 19 deletion
|
erlotinib • linsitinib (ASP7487)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
12/11/2018
Initiation :
06/18/2012
Primary completion :
04/01/2014
Completion :
04/01/2014
mTOR • IR
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
Phase 2
Merrimack Pharmaceuticals
Completed
Last update posted :
09/18/2018
Initiation :
05/01/2015
Primary completion :
08/01/2018
Completion :
08/01/2018
IGF1
|
gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)
Phase 2
Astellas Pharma Inc
Completed
Last update posted :
09/05/2018
Initiation :
03/04/2011
Primary completion :
07/01/2013
Completion :
03/11/2015
EGFR
|
EGFR mutation
|
erlotinib • linsitinib (ASP7487)
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
08/15/2018
Initiation :
09/30/2008
Primary completion :
02/17/2010
Completion :
02/17/2010
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR negative
|
dalotuzumab (MK 0646)
Phase 2
Merck Sharp & Dohme LLC
Completed
Last update posted :
08/08/2018
Initiation :
12/24/2007
Primary completion :
06/01/2010
Completion :
03/07/2012
KRAS
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression
|
Erbitux (cetuximab) • irinotecan • dalotuzumab (MK 0646)
Phase 2
Eli Lilly and Company
Completed
Last update posted :
06/06/2018
Initiation :
06/01/2007
Primary completion :
03/01/2009
Completion :
03/01/2009
KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3
|
KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1
|
Erbitux (cetuximab) • cixutumumab (IMC A12)
Phase 2
Eli Lilly and Company
Completed
Last update posted :
06/06/2018
Initiation :
08/01/2008
Primary completion :
03/01/2012
Completion :
02/01/2015
ER • PGR
|
tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • cixutumumab (IMC A12)
Phase 1
National Cancer Institute (NCI)
Withdrawn
Last update posted :
07/02/2017
Initiation :
07/28/2010
Primary completion :
04/04/2012
Completion :
04/04/2012
AFP
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
Phase 2
Merck Sharp & Dohme LLC
Completed
Last update posted :
05/31/2017
Initiation :
09/17/2010
Primary completion :
10/15/2013
Completion :
10/15/2013
HER-2 • ER
|
ER positive • HER-2 negative
|
exemestane • Taltorvic (ridaforolimus) • dalotuzumab (MK 0646)
Phase 1
Centaurus Biopharma Co., Ltd.
Unknown status
Last update posted :
03/09/2017
Initiation :
03/01/2016
Primary completion :
03/01/2018
Completion :
03/01/2018
ALK
|
ALK positive • ALK rearrangement
|
Xalkori (crizotinib) • conteltinib (SY-707)
Phase 2
NantCell, Inc.
Completed
Last update posted :
10/27/2016
Initiation :
03/01/2009
Primary completion :
01/01/2011
Completion :
06/01/2012
KRAS
|
KRAS mutation
|
5-fluorouracil • irinotecan • leucovorin calcium • ganitumab (AMG 479) • conatumumab (AMG 655)
Phase 2
Alliance for Clinical Trials in Oncology
Withdrawn
Last update posted :
06/28/2016
Initiation :
08/01/2012
Primary completion :
08/01/2012
UGT1A1
|
UGT1A1*28 • UGT1A1*1*1
|
5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ganitumab (AMG 479)
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
04/04/2016
Initiation :
02/01/2009
Primary completion :
06/01/2010
Completion :
05/01/2011
EGFR
|
EGFR mutation • EGFR amplification
|
erlotinib • dalotuzumab (MK 0646)
Phase 2
Translational Research in Oncology
Completed
Last update posted :
01/11/2016
Initiation :
01/01/2009
Primary completion :
05/01/2013
Completion :
05/01/2013
MUC16
|
MUC16 elevation
|
ganitumab (AMG 479)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
11/04/2015
Initiation :
05/01/2008
Primary completion :
06/01/2013
Completion :
10/01/2015
PTEN • AKT1 • KDR • IRS1
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
Phase 2
Pfizer
Withdrawn
Last update posted :
05/04/2015
Initiation :
04/01/2009
Primary completion :
09/01/2011
Completion :
09/01/2011
HER-2
|
docetaxel • figitumumab (CP-751,871)